Work

PERK Inhibition Mitigates Restenosis and Thrombosis

Year: 2020

Type: article

Abstract: Developing endothelial-protective, nonthrombogenic antirestenotic treatments has been a challenge. A major hurdle to this has been the identification of a common molecular target in both smooth muscle cells and endothelial cells, inhibition of which blocks dysfunction of both cell types. The authors' findings suggest that the PERK kinase could be such a target. Importantly, PERK inhibition mitigated both restenosis and thrombosis in preclinical models, implicating a low-thrombogenic antirestenotic paradigm.

Source: JACC Basic to Translational Science

DOI: 10.1016/j.jacbts.2019.12.005

Authors: Bowen Wang, Mengxue Zhang, Go Urabe, Yitao Huang, Guojun Chen, Debra Wheeler, David J. Dornbos, Allyson Huttinger, Shahid M. Nimjee, Shaoqin Gong, Lian-Wang Guo, K. Craig Kent

Institutions: The Ohio State University Wexner Medical Center, The Ohio State University, University of Wisconsin–Madison, Wisconsin Institutes for Discovery

Language: English

Topic: Coronary Interventions and Diagnostics

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,400

Funders: American Heart Association, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute

Awards: Targeted Therapy of Neuroendocrine Cancers Via the Notch Signaling Pathway, BET Bromodomain proteins as Novel Epigenetic Targets for prevention of Intimal Hyperplasia after Vascular Surgery, Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstruction, Targeting PERK: An Endothelium-Protective Stent-Free Strategy for Mitigation of Intimal Hyperplasia After Vascular Surgery

OpenAlex ID: W3008772348

FWCI: 4.108

Cites: 54

Cited by: 27

Related to: 10